RAPT Therapeutics

Yahoo Finance • 14 days ago

Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 25 days ago

Citi lifts GSK target price but keeps neutral stance after rally

Citi lifts GSK target price but keeps neutral stance after rally Proactive uses images sourced from Shutterstock Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sha... Full story

Yahoo Finance • last month

Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)

BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 4 months ago

RAPT Therapeutics GAAP EPS of -$0.65 beats by $0.17

* RAPT Therapeutics press release [https://seekingalpha.com/pr/20296636-rapt-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights] (RAPT [https://seekingalpha.com/symbol/RAPT]): Q3 GAAP EPS of -$0.65 beats by $... Full story

Yahoo Finance • 4 months ago

RAPT Therapeutics prices equity offering at $30 per share

* RAPT Therapeutics (NASDAQ:RAPT [https://seekingalpha.com/symbol/RAPT]) priced [https://seekingalpha.com/pr/20274668-rapt-therapeutics-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of ~8.33M share... Full story

Yahoo Finance • 4 months ago

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel ther... Full story

Yahoo Finance • 4 months ago

RAPT Therapeutics announces proposed public offering

* RAPT Therapeutics (NASDAQ:RAPT [https://seekingalpha.com/symbol/RAPT]) announced [https://seekingalpha.com/pr/20274354-rapt-therapeutics-announces-proposed-public-offering-of-common-stock] on Tuesday that it has commenced an underwritt... Full story

Yahoo Finance • 4 months ago

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel ther... Full story

Yahoo Finance • 5 months ago

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for... Full story

Yahoo Finance • 5 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 5 months ago

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies fo... Full story

Yahoo Finance • 8 months ago

RAPT Therapeutics adds two new directors to board

SOUTH SAN FRANCISCO - RAPT Therapeutics, Inc. (NASDAQ:RAPT) appointed Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors, the clinical-stage biopharmaceutical company announced Monday. According to InvestingPro... Full story

Yahoo Finance • 8 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for... Full story

Yahoo Finance • 9 months ago

Rapt Therapeutics announces effective date for 1-for-8 reverse stock split

RAPT Therapeutics (RAPT) announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company’s common stock will co... Full story

Yahoo Finance • 9 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing nov... Full story

Yahoo Finance • 12 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies f... Full story

Yahoo Finance • last year

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other Worst 52-Week Low Sto... Full story

Yahoo Finance • last year

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other worst 52-week low stock... Full story

Yahoo Finance • 2 years ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at fourweeksFurther deepening of response in percent change i... Full story